HK inno.N Corporation (KOSDAQ:195940)

Market Cap	1.53T +56.3%
Revenue (ttm)	839.63B +12.9%
Net Income	41.49B +58.1%
EPS	1,451.65 +96.5%
Shares Out	28.33M
PE Ratio	37.20
Forward PE	17.08
Dividend	350.00 (0.65%)
Ex-Dividend Date	n/a

Volume	153,063
Average Volume	262,625
Open	54,600
Previous Close	55,100
Day's Range	53,400 - 54,900
52-Week Range	31,650 - 58,600
Beta	0.68
RSI	49.06
Earnings Date	Feb 11, 2026

About HK inno.N

HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, no...

• Industry: Medical Care Facilities
• Sector: Healthcare
• Founded: 1984
• Employees: 1,695
• Stock Exchange: KOSDAQ
• Ticker Symbol: 195940

Financial Performance

In 2021, HK inno.N's revenue was 769.79 billion, an increase of 28.63% compared to the previous year's 598.45 billion. Earnings were 21.35 billion, a decrease of -23.49%.